Business Wire

ADVA

9.4.2020 09:02:04 CEST | Business Wire | Press release

Share
Serverius deploys ADVA FSP 3000 TeraFlex™ for 1200G transport

ADVA (FSE: ADV) today announced that Serverius, one of the Netherlands’ largest data center service suppliers, is leveraging its FSP 3000 TeraFlex™ terminal to massively increase the capacity of its deployed infrastructure. By utilizing the industry’s most comprehensive and scalable solution, Serverius is answering fierce growth in demand for its connectivity, colocation and data security services. With its ultra-flexible bandwidth modulation, TeraFlex™ enables Serverius to harness previously unused spectrum, unlocking new value in its existing fiber network. The highly compact 1RU platform optimizes all optical paths and ensures the lowest cost per bit for all fiber links. By enabling super-channels of up to 1200Gbit/s and a total capacity of 7.2Tbit/s, TeraFlex™ empowers Serverius to provide Dutch and international enterprises with a new level of capacity and throughput.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200409005014/en/

“By harnessing the very latest innovation, we’re bringing a new level of bandwidth capacity and service quality to businesses throughout the Netherlands and beyond. The ADVA FSP 3000 TeraFlex™ is key to our mission of providing world-class data center connectivity. And, with its space- and power-efficiency, it also ensures that our services remain highly affordable today and sustainable for the future,” said Sergey Petukhin, head of connectivity infrastructure, Serverius. “This deployment unlocks the full potential of our network. Now we can meet rapidly rising data demand and be sure that our infrastructure is ready to scale when our clients need even more capacity. What’s more, the openness and programmability of TeraFlex™ mean that we’re free to harness the benefits of tomorrow’s innovation without being tied to any one vendor.”

Serverius’ new solution is built on the ADVA FSP 3000 TeraFlex™, which uses software-defined fractional QAM modulation and adaptive baud rate capabilities to support 1200Gbit/s streams. By retrieving optical channel conditions via network telemetry, the platform determines the best possible capacity and spectral efficiency for each light path. This enables Serverius to exploit untapped capacity in its existing infrastructure without the cost of a complete system upgrade. Each 1RU terminal can also support up to three cards, providing easy access to capacity up to 7.2Tbit/s. What’s more, Serverius is also harnessing ADVA’s MicroMux™QSFP28 plug, which converts 100GbE client ports into ten 10GbE ports, further reducing cost, rack space and operational complexity. Cloud solution specialists Exclusive Networks also played a key role in deploying the technology.

“Serverius has a clear vision of what businesses need and a bold strategy for delivering it. By leveraging our most advanced technologies to massively increase the capacity of its fiber plant, the Netherlands’ fastest-growing cloud connectivity provider is offering its customers a vital competitive edge. With our TeraFlex™, Serverius has the power to flexibly respond to soaring data requirements and help businesses achieve their full potential,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “The strong and long-lasting relationship we have with the Serverius team was also crucial to the success of this project. By working closely with their people, we’ve been able to ensure that the new solution meets all of their particular needs while maximizing the value of their deployed infrastructure.”

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye